As of 2025-10-13, the EV/EBITDA ratio of Flexion Therapeutics Inc (FLXN) is -7.27. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FLXN's latest enterprise value is 568.53 mil USD. FLXN's TTM EBITDA according to its financial statements is -78.25 mil USD. Dividing these 2 quantities gives us the above FLXN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.6x - 14.8x | 13.1x |
| Forward P/E multiples | 12.8x - 19.3x | 16.6x |
| Fair Price | (62.26) - (70.71) | (71.02) |
| Upside | -345.9% - -379.3% | -380.5% |
| Date | EV/EBITDA |
| 2025-10-10 | -7.27 |
| 2025-10-09 | -7.31 |
| 2025-10-08 | -7.33 |
| 2025-10-07 | -7.34 |
| 2025-10-06 | -7.35 |
| 2025-10-03 | -7.35 |
| 2025-10-02 | -7.35 |
| 2025-10-01 | -7.35 |
| 2025-09-30 | -7.34 |
| 2025-09-29 | -7.34 |
| 2025-09-26 | -7.33 |
| 2025-09-25 | -7.32 |
| 2025-09-24 | -7.34 |
| 2025-09-23 | -7.34 |
| 2025-09-22 | -7.35 |
| 2025-09-19 | -7.34 |
| 2025-09-18 | -7.34 |
| 2025-09-17 | -7.32 |
| 2025-09-16 | -7.33 |
| 2025-09-15 | -7.33 |
| 2025-09-12 | -7.32 |
| 2025-09-11 | -7.32 |
| 2025-09-10 | -7.30 |
| 2025-09-09 | -7.29 |
| 2025-09-08 | -7.30 |
| 2025-09-05 | -7.30 |
| 2025-09-04 | -7.29 |
| 2025-09-03 | -7.27 |
| 2025-09-02 | -7.25 |
| 2025-08-29 | -7.27 |
| 2025-08-28 | -7.28 |
| 2025-08-27 | -7.27 |
| 2025-08-26 | -7.27 |
| 2025-08-25 | -7.26 |
| 2025-08-22 | -7.26 |
| 2025-08-21 | -7.24 |
| 2025-08-20 | -7.26 |
| 2025-08-19 | -7.26 |
| 2025-08-18 | -7.26 |
| 2025-08-15 | -7.26 |
| 2025-08-14 | -7.26 |
| 2025-08-13 | -7.27 |
| 2025-08-12 | -7.26 |
| 2025-08-11 | -7.24 |
| 2025-08-08 | -7.24 |
| 2025-08-07 | -7.24 |
| 2025-08-06 | -7.24 |
| 2025-08-05 | -7.23 |
| 2025-08-04 | -7.24 |
| 2025-08-01 | -7.21 |